ISInd-Swift Laboratories532305Preferential allotment

Monitoring agency report on Rs.137.20 crore warrant proceeds: no deviation from stated objects

CARE Ratings has issued its monitoring agency report for the quarter ended 30 September 2026 on the proceeds of Ind-Swift Laboratories' preferential issue of 70 lakh fully convertible warrants.

By ScoutQuest · Tue 3 Nov 2026, 2:56 PM IST · 3 min read

Issue size

Rs.137.20 crore (70 lakh fully convertible warrants)

Amount received till 30 September 2026

Rs.34.300 crore

Amount used during quarter / unutilised at quarter end

Used: Rs.15.600 crore; unutilised: Rs.18.700 crore

What the update covers

• CARE Ratings Limited, the monitoring agency, has reported on the use of proceeds of a preferential issue of 70 lakh fully convertible warrants of Ind-Swift Laboratories Ltd.
• Issue size: Rs.137.20 crore. Date of allotment: September 17, 2026. The issue period runs 18 months from the date of allotment.
• This is the first monitoring agency report on utilisation of these proceeds. CARE states there is no deviation from the objects of the issue and no material deviation.
• The report was reviewed by the Audit Committee and taken on record by the Board of Directors.

The stated objects and their cost (as per the offer document)

• Expansion of existing manufacturing facility and setting up of a new warehouse: Rs.41.40 crore.
• Research & Development: Rs.2.00 crore.
• Technology upgradation: Rs.1.50 crore.
• Investment in subsidiary: Rs.5.00 crore.
• Working capital requirements: Rs.53.00 crore.
• General corporate purposes: Rs.34.30 crore.
• Total: Rs.137.20 crore. No revised cost has been shown against any head.

How much has come in and how much has been used

• Amount raised till September 30, 2026: Rs.34.300 crore, against the Rs.137.200 crore proposed in the offer document.
• Amount utilised during the quarter: Rs.15.600 crore. Total unutilised at the end of the quarter: Rs.18.700 crore.
• Expansion of manufacturing facility and warehouse: Rs.6.315 crore used, on civil works, architectural and design services, advances for machinery and equipment, and related installation and ancillary services at Jawaharpur, Derabassi (PB) and Jammu (J&K).
• Research & Development: Rs.0.335 crore used, on pilot scale formulation equipment for new pharmaceutical formulations.
• Technology upgradation: nil utilised during the quarter.
• Investment in subsidiary: Rs.4.853 crore invested in ISLL Middle East L.L.C-FZ, Dubai.
• Working capital: Rs.3.989 crore used, such as purchases of raw material.
• General corporate purposes: Rs.0.108 crore used, towards monitoring agency report-related expenses.
• Interest income earned on fixed deposits created out of unutilised proceeds is excluded from these utilisation figures: Rs.0.0022 crore in the expansion head and Rs.0.0013 crore in the working capital head.

The point to note

• CARE states that the Rs.4.853 crore invested in the foreign subsidiary, ISLL Middle East L.L.C-FZ, Dubai, could not be independently confirmed at the end-use level, as supporting documents including the subsidiary's bank statements and underlying invoices were not available to it. CARE therefore relies on the management and the chartered accountant certificate for confirmation of end-use.
• The Board's comment is that the Dubai entity is the company's marketing arm set up to capture the Middle East market, and that the funds transferred are being used for promotion of the company's business.
• On whether all government or statutory approvals related to the objects have been obtained, the reply is No. The management certificate states that approvals mentioned in the placement document are in place, and that approvals related to capex will be obtained as and when required as per project status.
• The chartered accountant certificate is from M/s Rattan Kaur & Associates, the statutory auditors, dated October 27, 2026.

What this means for a retail reader

• This is a routine quarterly disclosure that lets investors track whether money raised through the warrant issue is being spent on the purposes stated at the time of the issue.
• The key numbers to track each quarter are the Rs.34.300 crore received so far, the Rs.15.600 crore used this quarter and the Rs.18.700 crore still unutilised, since a large unutilised balance means the spending is still ahead.
• The verification caveat on the subsidiary money is a disclosure point to keep in mind; it does not change the agency's conclusion of no deviation from the objects.

Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.

About ScoutQuest · Logos provided by Logo.dev